Table 2.

Comparing study features of anti-TNF trials in pSpA

	CRESPA trial13 55	ABILITY-2 trial33	Paramarta et al35 54
Inclusion criteria	ASAS classification criteria + rheumatologist diagnosis	ASAS classification criteria + no prior psoriasis, PsA or AS	ESSG or Amor criteria + no AS or PsA
Multicenter study	No	Yes	No
Anti-TNF-blocking agent	Golimumab	Adalimumab	Adalimumab
Number of included patients	60	165	40
Symptom duration (mean ± SD years)	5.2 weeks ±2.8 vs 4.4 weeks ±2.0	6.6 years ±6.3 vs 7.7 years ±7.9	7.9 years ±9.3 vs 6.7 years ±6.2
Primary end point % patients in clinical remission at w24 % patient PSpARC40 response at w12 PGA of disease activity	Absence of arthritis, dactylitis and enthesitis at w24 75% vs 20% (p<0.001) 57.5% vs 20% (p=0.0069) −50.0 vs −20.0 (p=0.0015)	PSpARC40 response criteria at w12 ND 39% vs 20% (p=0.006) −27.5 vs −16.4 (p=0.003)	PGA of disease activity ND ND −31.0 vs −5.9 (p=0.001)
Withdrawal strategy Relapse rate after discontinuation	Yes 47%	No	Yes 73%

AS, ankylosing spondylitis; ASAS, Assessment of Spondyloarthritis International Society; ESSG criteria, European Spondylitis Study Group criteria; PSpARC40 response criteria, peripheral spondyloarthritis 40% response criteria.